The magical market of datably medicine, experts: Nearly half of Chinese men have ED symptoms?

The pharmaceutical industry is experiencing a trough. How can I find new vitality in the predicament? Some pharmaceutical companies have found directions.

"In addition to the women's market, we look forward to the health of men who have received lower attention in the sexual relationship, and we can also get more and more face -to -face." Fan Wendi, senior vice president of Kellen, announced on August 27th that the new trend of Columbia Pharmaceuticals was announced on August 27th. Essence

On August 27, the "OKMAN" brand under Kelon was officially unveiled in Hangzhou. The first heavy product launched this time is the just -approved citrate citrate Sidama Crusher Tablets (product name Wan Aida®) Essence From the perspective of the global market, the non -preparation of West has a huge user foundation, which stems from the "male" incident in the two sex -erectile dysfunction. Colom intends to use Wan Aida®, Ai Shida®, Ai Yueda® to drive as the flagship, and professionally open up therology market.

Deng Tingting, the person in charge of the Corey market brand, said: The OKman brand will not only pay attention to caring for men, but also pay attention to caring for women from the perspective of men. Therefore, the OKMAN brand has initially designed a more comprehensive product matrix, including more than 20 products such as male medicine, nursing dailyization, and family planning products.

On the evening of August 29, Colom Pharmaceutical disclosed the semi -annual report: In the first half of 2022, the company realized revenue of 9.125 billion yuan, an increase of 10.84%year -on -year; net profit was 868 million yuan, a year -on -year increase of 76.15%.

As a traditional large infusion, raw medicine, and generic drug production enterprises, Kelun Pharmaceutical's "Men's Great Health" journey was very sudden, but it just stepped on the time point.

Upgraded battle for male medicine

The men's medication market is an area where ordinary people are ashamed to mention but have strong demand.

The non -preparations of the Western Naga in the treatment of male ED (erectile dysfunction) performed very amazing in the domestic market. According to Miner.com, among the TOP20 brand of China Online Pharmacy terminal chemicals, the first non -imitation medicine Baiyun Mountain in China Jin Ge "with a market share of 2.06%, the growth rate of 42.27%was the top of the list.

Jiang Hui, Secretary of the Party Committee of the First Hospital of Peking University, said: Due to some problems such as the low number of sperm caused by some social pressure, bad habits, smoking, obesity, excessive drinking, and decline in sexual gonades, the demand for ED products is constantly rising.

Jiang Hui, Secretary of the Party Committee of the First Hospital of Peking University

Dai Jican, chief physician of the Renji Hospital affiliated to Shanghai Jiaotong University Medical College, directly pointed out that in my country, nearly half of men have ED symptoms, and the incidence of ED is increasing with age.

Westland was originally a research medicine in Pfizer, and the product was named Wan Aike®. Since its listing in 1998, Wan Aike® has sold more than $ 1 billion in almost a year. After the patent expired in 2012, Wan Aike® encountered the fierce attack of global generic drugs. The Chinese market was mainly imitation drug competitors such as Guangyao Baiyun Mountain and Qilu Pharmaceutical.

Pfizer fought and retreated. In October 2020, it was launched to take a more convenient oral collapse tablets, trying to continue to control some of the Chinese market. At the beginning of the listing, Pfizer's Western Na Na Naipan film was as high as 128 yuan per capsule, which was still welcomed by the market.

This time Collenone took out the domestic Western Nydishi collapse and participated in the competition in the market segment. Coron Pharmaceutical shows at the product conference site. This orange -flavored mouthpiece packaging is lightweight, the secret is better, and it does not need to drink water for service; it takes effect as soon as 14 minutes. Hours, multi -level people, including the elderly, are applicable.

Coron Pharmaceutical's impact on Westland's non -market, not only the product of the collapse film. At the press conference, Colom revealed that the company is developing Westland's non -mouthproof membrane. Deng Tingting said: "Compared with the lapse tablet, the convenience and feelings of the oral soluble film products will be better, and the sense of trend will be stronger."

Market breeding new brand

This time, Keron took out not only a male medicine, but also launched a new male health brand: OKMAN.

The entire male medication market is actually closely related to the economic environment. The impact of home isolation and other epidemics has changed people's living habits, and the increase in the time of the family pays more attention to family relationships.

In the view of Jiang Nanchun, the founder and chairman of Focus Media, the birth of the Okman brand is "coincident". He said that there are nearly 400 million people in the middle class above or above in China, and they are experiencing a transition from cost -effective to expensive consumption demands. The emergence of OKMAN has the opportunity to share the 100 billion -level market opportunities.

According to Mine.com data, in 2021, the sales of male ED drugs in terminal pharmacies across the country exceeded 3.6 billion yuan, ranking first, of which naturally western non -preparations. However, other anti -ED drugs also have a large market capacity. Among the OKMAN brands launched by Coron Pharmaceutical, in addition to Western Na Naipan, there are two generic drug products, which are the non -videline hydrochloride tablets for ED, and the only hydrochloric acid on the market. Potidine film.

In addition, Okman also has more than 20 products under R & D, including hair loss products, individual protection products, etc. Men's improved toothpaste, mouthwash, and men's mask will also be launched one after another. Deng Tingting said: "We believe that men's health should not only be limited to physiological, but also pay attention to the beauty of health like women."

At the listing meeting of Westland's non -mouthproof films, Colom Pharmaceuticals and Ali Health and JD Health conducted a start -up contract. They reached commercial and Internet with Inte, Canton Group, and Yuanxin Technology, Baidu Health, and Ark Kenkens. Signing and promoting strategic contracts. "The launching sales of the omni -channel of Westland's non -mouthpiece will be the sales growth point of the second half of the year." In the semi -annual report, Crees Pharmaceutical said so.

Multi -field cross -border progress steadily

At the moment when economic fluctuations are large, many Biotech companies are saving expenditure by cutting off pipelines and cutting expenses, just to "survive." Coron Pharmaceutical establishes a new brand and moves into the great health of men, which is a beneficial expansion from its own advantages.

Colom is actually a beneficiary of the collection system. In the first half of 2022, the company achieved revenue of 9.125 billion yuan, an increase of 10.84%year -on -year; net profit was 868 million yuan, a year -on -year increase of 76.15%. After the seven rounds of national collection, Colom's 36 varieties and 52 specifications were shortlisted, which became a typical typical of domestic pharmaceutical companies.

At the end of the innovative medicine, Colom's performance is also very amazing. When China's original research products encountered difficulties in the sea, Columbia Pharmaceutical subsidiaries Coronbuta reached two overseas authorization cooperation with Meridon this year with Meridon. The total milestone amount exceeded 2 billion US dollars.

Coron also has a solid basic disk. In the first half of this year, the proportion of closed infusion increased by 2.87%, and profits increased year -on -year; the antibiotic raw materials that began to lay out more than ten years ago increase steadily. It is reported that the Sichuan -Ning Biological IPO application has been reviewed and approved by the Shenzhen Stock Exchange GEM Listed Committee.

Unlike the logic of "burning money" in domestic innovation pharmaceutical companies and obtaining valuations, Coron Pharmaceutical's cross -border does not pursue "overnight", but to advance high -end imitation, improvement innovation and source innovation. Essence When it is appropriate, there is also a wave of big health, which is also a rare business pattern in domestic pharmaceutical companies.

Crown Pharmaceutical's cross -border may bring reference to other companies.

### Male ED Symptoms#

- END -